esmocongress.org

ADVANCED PROGRAMME

ESMO 2014

Madrid, Spain 26-30 SEPTEMBER 2014

IMPORTANT DEADLINES 07 May 2014 Abstract submission and travel grant applications 18 June 2014 Early registration

Organiser 23 July 2014 Group registration, participant names to be given 20 August 2014 Late-breaking abstract submission 20 August 2014 Late registration BASIC SCIENCE AND TRANSLATIONAL RESEARCH

Saturday, 27 September 2014 Monday, 29 September 2014 10:30/ PATIENT CASES 11:00/ SPECIAL SYMPOSIUM 11:30 Cancer evolution: What can we learn from N=1 12:30 Genomic instability from bench to bedside molecular studies? Chair: Sheila Singh, Hamilton, ON, Canada Co-Chairs: Michael Taylor, Toronto, ON, Canada and Tariq Enver, Co-Chair: Charles Swanton, London, UK London, UK Introduction Evolution of acute lymphoblastic leukemia (ALL) in identical twins Charles Swanton, London, UK Tariq Enver, London, UK The emerging role of HELQ in homologous recombination repair Clonal evolution of childhood cancers in ovarian cancer Michael Taylor, Toronto, ON, Canada Rebecca Burrell, London, UK Discussion Replication stress and DNA damage response in solid tumours Jiri Bartek, Copenhagen, Denmark The interface between cancer numerical and structural Sunday, 28 September 2014 chromosomal instability: Mechanisms accelerating cancer diversity 09:15/ JOINT SYMPOSIUM: ESMO - JSMO 10:45 How to implicate genome sequencing data in oncology René Medema, Amsterdam, Netherlands Co-Chairs: Jean-Yves Douillard, St. Herblain, France and Targeting cancer aneuploidy: Light at the end of the tunnel? Atsushi Ohtsu, Kashiwa, Japan Tak Mak, Toronto, ON, Canada Introduction Conclusions and clinical perspectives Jean-Yves Douillard, St. Herblain, France Sheila Singh, Hamilton, ON, Canada Potentially druggable gene alterations in gastrointestinal cancer Tatsuhiro Shibata, Tokyo, Japan A new molecular taxonomy for colorectal cancer – What are the therapeutic implications? To be announced New insight of sequencing data in lung cancer Kazuto Nishio, Osaka, Japan Overcoming implementation challenges of personalised cancer therapy in patients with breast cancer Fabrice André, Villejuif, France Conclusions Atsushi Ohtsu, Kashiwa, Japan 13:00/ KEYNOTE LECTURE 13:45 Reclassifying cancer through genomics Chair: Jos Jonkers, Amsterdam, Netherlands Speaker: Michael Stratton, London, UK

SCIENTIFIC COMMITTEE Charles Swanton, London, UK, Chair Jiri Bartek, Copenhagen, Denmark Jos Jonkers, Amsterdam, Netherlands René Bernards, Amsterdam, Netherlands Tak Mak, Toronto, ON, Canada Rebecca Burrell, London, UK Carlo Maley, San Franscisco, CA, USA Carlos Caldas, Cambridge, UK Sheila Singh, Hamilton, ON, Canada Robert Gatenby, Tampa, FL, US Yosef Yarden, Rehovot, Israel Ramaswamy Govindan, St. Louis, MO, US

Session timings may be subject to change within the same day 9 BREAST CANCER

Saturday, 27 September 2014 Sunday, 28 September 2014 09:00/ EDUCATIONAL SESSION 08:00/ PATIENT CASES 10:30 Update in the management of metastatic breast 09:00 Targeting intrinsic subtypes of metastatic breast cancers cancer: The spectrum of sensitivity to endocrine Chair: Angelo Di Leo, Prato, Italy therapy Co-Chair: Hernan Cortes-Funes, Madrid, Spain Co-Chairs: Philippe Bedard, Toronto, ON, Canada and Integration of molecular analyses in the management of Javier Cortes, Barcelona, Spain metastatic breast cancer Overcoming resistance in ER positive disease Nicholas Turner, London UK Philippe Bedard, Toronto, ON, Canada Hormonal therapy Dealing with heterogeneity of triple negative breast cancer: From Ian Smith, London, UK luminal androgen receptor to mesenchimal stem like subtype Optimal therapy for R2 positive Javier Cortes, Barcelona, Spain Angelo Di Leo, Prato, Italy Discussion 11:00/ EDUCATIONAL SESSION 09:15/ SPECIAL SYMPOSIUM 12:30 Management of breast cancer in specific populations 10:45 Residual disease after neoadjuvant therapies Chair: Fatima Cardoso, Lisbon, Portugal Chair: Evandro de Azambuja, Brussels, Belgium Co-Chair: to be announced Co-Chair: Suzette Delaloge, Villejuif, France Management of breast cancer in elderly patients Introduction Etienne Brain, Saint Cloud, France Suzette Delaloge, Villejuif, France Management of breast cancer in very young and pregnant Quantifying post-neo adjuvant therapy residual disease and its women impact on relapse risk Sybille Loibl, Neu-Isenburg, Germany Fraser Symmans, Houston, TX, US Management of breast cancer in males Biological profiling of residual disease Fatima Cardoso, Lisbon, Portugal Frederique Penault-Llorca, Clermont-Ferrand, France 16:00/ EDUCATIONAL SESSION (REPETITION) Molecular imaging: Are we able to predict for residual disease? 17:30 Management of breast cancer in specific populations Andreas Makris, Northwood, UK Chair: Fatima Cardoso, Lisbon, Portugal How to design clinical trials in a post neo-adjuvant setting? Co-Chair: to be announced Andrew Tutt, London, UK Management of breast cancer in elderly patients Conclusions and clinical perspectives Etienne Brain, Saint Cloud, France Evandro de Azambuja, Brussels, Belgium Management of breast cancer in very young and pregnant 14:15/ EDUCATIONAL SESSION (REPETITION) women 15:45 Update in the management of metastatic breast Sybille Loibl, Neu-Isenburg, Germany cancers Management of breast cancer in males Chair: Angelo Di Leo, Prato, Italy Fatima Cardoso, Lisbon, Portugal Co-Chair: Hernan Cortes-Funes, Madrid, Spain Integration of molecular analyses in the management of metastatic breast cancer Nicholas Turner, London UK Hormonal therapy Ian Smith, London, UK Optimal therapy for R2 positive Angelo Di Leo, Prato, Italy

SCIENTIFIC COMMITTEE (EARLY STAGE) Evandro De Azambuja, Brussels, Belgium, Chair Hatem Azim, Brussels, Belgium Sabine C. Linn, Amsterdam, Netherlands Agusti Barnadas, Barcelona, Spain Carlo Palmieri, Liverpool, UK Fatima Cardoso, Lisbon, Portugal Alastair Thompson, Dundee, UK Boon Chua, Melbourne, Australia Andrew Tutt, London, UK Angelo Di Leo, Prato, Italy Giuseppe Viale, Milan, Italy Peter Dubsky, Vienna, Austria

10 Session timings may be subject to change within the same day Monday, 29 September 2014 08:00/ CHALLENGE YOUR EXPERT (CYE) 14:15/ JOINT SYMPOSIUM: ESMO - ESTRO - ESSO 09:00 Adjuvant treatment of breast cancer 15:45 Integration of local therapy with systemic treatment in Speaker: Martine Piccart, Brussels, Belgium oligometastatic breast cancer Co-Chairs: Christoph Zielinski, Vienna, Austria; Philip Poortmans, 09:15/ SPECIAL SYMPOSIUM Tilburg, Netherlands and Riccardo A. Audisio, St. Helens, UK 10:45 Cancer immunotherapy in breast cancer: Dream or Introduction reality? Christoph Zielinski, Vienna, Austria Chair: Giuseppe Curigliano Milan, Italy Co-Chair: Sherene Loi, Melbourne, Australia Combining systemic treatment with radiation therapy: Quantifying the therapeutic gain Introduction Per Karlsson, Gothenburg, Sweden Giuseppe Curigliano Milan, Italy Design of clinical trials integrating local treatments with systemic Modulation of immune response in breast cancer and clinical therapy for M1 disease implications of tumour dormancy To be announced Sherene Loi, Melbourne, Australia The role of surgery for M1 breast cancer Diagnostic and therapeutic implications of tumour-infiltrating lymphocytes in breast cancer Marjut Leidenius, Helsinki, Finland Carsten Denkert, Berlin, Germany The role of radiation therapy for M1 breast cancer Philip Poortmans, Tilburg, Netherlands Contribution of immune response to anti-tumour effect of chemotherapy Conclusions Carmen Criscitiello, Naples, Italy Riccardo A. Audisio, St. Helens, UK Design of the ideal trial with immunotherapeutics 16:00/ PATIENT CASES Giuseppe Curigliano Milan, Italy 17:00 Challenges in managing breast cancer in young Conclusions and clinical perspectives patients Sherene Loi, Melbourne, Australia Co-Chairs: Hatem A. Azim, Brussels, Belgium; Marco Colleoni, Milan, Italy and Sabine Linn, Amsterdam, Netherlands Genetic testing: When and for whom? Sabine Linn, Amsterdam, Netherlands Fertility counselling: What are the options? Hatem A. Azim, Brussels, Belgium, Optimal adjuvant hormonal therapy in premenopausal women Marco Colleoni, Milan, Italy Discussion Tuesday, 30 September 2014 08:00/ CYE (REPETITION) 09:00 Adjuvant treatment of breast cancer Speaker: Martine Piccart, Brussels, Belgium

SCIENTIFC COMMMITEE (METASTATIC) Giuseppe Curigliano, Milan, Italy, Chair Philippe Bedard, Toronto, ON, Canada Per Karlsson, Gothenburg, Sweden Javier Cortes, Barcelona, Spain Antonio Llombart, Valencia, Spain Carmen Criscitiello, Milan, Italy Sherene Loi, Melbourne, Australia Carsten Denkert, Berlin, Germany Sibylle Loibl, Neu-Isenburg, Germany Luca Gianni, Milan, Italy Nicholas Turner, London, UK Roger Gomis, Barcelona, Spain

Session timings may be subject to change within the same day 11 CNS TUMOURS

Sunday, 28 September 2014 09:15/ EDUCATIONAL SESSION 14:15/ SPECIAL SYMPOSIUM 10:45 Actual issues in neurooncology 15:45 Current concepts and future avenues in meningioma Chair: Roger Stupp, Zurich, Switzerland Chair: Jörg-Christian Tonn, Munich, Germany Co-Chair: Mario Campone, St. Herblain, France Co-Chair: Matthias Preusser, Vienna, Austria Brain metastases: To treat or not to treat? Introduction Roger Stupp, Zurich, Switzerland Jörg-Christian Tonn, Munich, Germany Molecular marker-based clinical decision-making today Meningioma: What can we learn from the biology for precision Michael Weller, Zurich, Switzerland medicine? Approaches to recurrent glioblastoma Michel Kalamarides, Paris, France Alba Brandes, Bologna, Italy Classification and molecular pathology of meningiomas Christian Mawrin, Magdeburg, Germany 11:45/ PATIENT CASES 12:45 Response, neurological function and other objectives in Radiotherapy of meningiomas the management of patients with brain metastases Damien Weber, Geneva, Switzerland Co-Chairs: Martin Bendszus, Heidelberg, Germany; Anthony Molecular targeted, systemic therapies for meningiomas Chalmers, Glasgow, UK, and Enrico Franceschi, Bologna, Italy Matthias Preusser, Vienna, Austria What type of radiotherapy is indicated in brain metastases? Conclusions and clinical perspectives Anthony Chalmers, Glasgow, UK Matthias Preusser, Vienna, Austria Systemic therapy instead or in addition to irradiation? Enrico Franceschi, Bologna, Italy Challenges and pitfalls in radiological response assessment of brain metastases Martin Bendszus, Heidelberg, Germany Discussion

SCIENTIFIC COMMITTEE Roger Stupp, Zurich, Switzerland, Chair Carmen Balaña, Barcelona, Spain Matthias Preusser, Vienna, Austria Elizabeth Cohen-Jonathan-Moyal, Toulouse, France Guido Reifenberger, Düsseldorf, Germany Enrico Franceschi, Bologna, Italy Joan Seoane, Barcelona, Spain Evanthia Galanis, Rochester, MN, USA Martin van den Bent, Rotterdam, Netherlands Khé Hoang-Xuan, Paris, France Colin Watts, Cambridge, UK Stefan Pfister, Heidelberg, Germany

12 Session timings may be subject to change within the same day DEVELOPMENTAL THERAPEUTICS

Saturday, 27 September 2014 Monday, 29 September 2014 09:15/ JOINT SYMPOSIUM: ESMO - CSCO 10:30/ PATIENT CASES 10:45 Global collaboration in phase I cancer drug 11:30 Demonstrating the emergence of resistance development Co-Chairs: Elisabeth de Vries, Groningen, Netherlands, and Co-Chairs: Yi-Long Wu, Guangzhou, China and Ruth Plummer, Newcastle upon Tyne, UK to be announced How to overcome drug resistance Introduction Ruth Plummer, Newcastle upon Tyne, UK Yi Long Wu, Guangzhou, China Molecular imaging to demonstrate changes in tumour Phase I cancer drug development in China characteristics over the time Jin Li, Shanghai, China Elisabeth de Vries, Groningen, Netherlands Phase I cancer drug development in Europe Discussion To be announced 13:00/ KEYNOTE LECTURE How can pharmaceutical companies facilitate this global effort? 13:50 Rational drug combinations To be announced Chair: Timothy Yap, Sutton, UK Lung Cancer Asia Study Group: East Concepts and pre-clinical proof of principle Yi-Long Wu, Guangzhou, China René Bernards, Amsterdam, Netherlands Conclusions Clinical results and future perspectives To be announced Jan Schellens, Amsterdam, Netherlands

Sunday, 28 September 2014 09:00/ SPECIAL SYMPOSIUM 10:30 Molecular profiling: Challenges and perspectives Chair: Christian Dittrich, Vienna, Austria Co-Chair: Jean-Charles Soria, Villejuif, France Introduction Jean-Charles Soria, Villejuif, France How to design the trials to meet the perspectives of personalised cancer medicine Sumithra Mandrekar, Rochester, NY, US Platforms for tumour sequencing: Pertinence and practicability Martijn Lolkema, Utrecht, Netherlands Overview of trials testing tumour molecular profiling Jean-Charles Soria, Villejuif, France Targets, targets everywhere but not a drug to give Udai Banerji, London, UK Conclusions and clinical perspectives Christian Dittrich, Vienna, Austria

SCIENTIFIC COMMITTEE Christian Dittrich, Vienna, Austria, Chair Ahmad Awada, Brussels, Belgium Ruth Plummer, Newcastle upon Tyne, UK Udai Banerji, Sutton, UK Roberto Salgado, Brussels, Belgium Elisabeth de Vries, Groningen, Netherlands Patrick Schöffski, Leuven, Belgium Elizabeth A. Eisenhauer, Kingston, ON, Canada Giampaolo Tortora, Verona, Italy Manuel Hidalgo, Madrid, Spain Christopher Twelves, Leeds, UK Annette K. Larsen, Paris, France

Session timings may be subject to change within the same day 13 FAMILIAL CANCERS AND GENETIC SYNDROMES

Saturday, 27 September 2014 Sunday, 28 September 2014 09:15/ SPECIAL SYMPOSIUM 09:15/ PATIENT CASES 10:45 Germline genetics: Important issues for oncologists 10:15 Clinical and ethical issues in cancer genetics Chair: Dominique Stoppa-Lyonnet, Paris, France Co-Chairs: Anneke Lucassen, Southampton, UK and Co-Chair: Rosalind Eeles, Sutton, UK Fred Menko, Amsterdam, Netherlands Introduction Early onset renal cancer Dominique Stoppa-Lyonnet, Paris, France Fred Menko, Amsterdam, Netherlands Current application of genetic variants to clinical management Ethical issues surrounding genetic results Gareth Evans, Sutton, UK Anneke Lucassen, Southampton, UK Considerations for the oncologist when referring for testing: Discussion Which tests are available and why? Thierry Frebourg, Rouen, France Genetic risk and its implications for cancer surveillance Rosalind Eeles, Sutton, UK Considerations for the oncologist when treating cancer patients with germline mutations Gillian Mitchell, Melbourne, Australia BOOKING YOUR Conclusions and clinical perspectives Rosalind Eeles, Sutton, UK OWN CONFERENCE TRAVEL IS EASY AS ABC WITH THE GLOBAL ONLINE BOOKING TOOL FROM STAR ALLIANCE CONVENTIONS PLUS

No matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to ESMO 2014 in Madrid.

SCIENTIFIC COMMITTEE And with over 21,900 flights a day to 1,329 Rosalind Eeles, Sutton, UK, Chair destinations across 195 countries, our 28 member Judith Balmaña, Barcelona, Spain Fred Menko, Amsterdam, Netherlands airlines extend the same choice to any future Elena Castro, Sutton, UK Gillian Mitchell, Melbourne, Australia conferences you are planning to attend. Gareth Evans, Manchester, UK Kenneth Muir, Coventry, UK Kari Hemminki, Heidelberg, Germany Dominique Stoppa-Lyonnet, Paris, France You can also save money when you book your Shirley Hodgson, London, UK Hans Vasen, Leiden, Netherlands flights. Simply quote the Convention Code SK07A03 and you plus one travelling companion will receive a special discount. Better still, no matter which Star Alliance member airline’s frequent flyer programme you belong to, you can earn and redeem miles across all 28 airlines.

For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to www.staralliance.com/conventionsplus

www.staralliance.com

14 Session timings may be subject to change within the same day Information correct as of 06/2013

SA_ConventionsPlus_AD_A4_2013-06_generic.indd 1 26.02.14 09:53 BOOKING YOUR OWN CONFERENCE TRAVEL IS EASY AS ABC WITH THE GLOBAL ONLINE BOOKING TOOL FROM STAR ALLIANCE CONVENTIONS PLUS

No matter where you are travelling from, the Star Alliance™ network offers you a wide choice of flights to ESMO 2014 in Madrid.

And with over 21,900 flights a day to 1,329 destinations across 195 countries, our 28 member airlines extend the same choice to any future conferences you are planning to attend.

You can also save money when you book your flights. Simply quote the Convention Code SK07A03 and you plus one travelling companion will receive a special discount. Better still, no matter which Star Alliance member airline’s frequent flyer programme you belong to, you can earn and redeem miles across all 28 airlines.

For more information, or to join the airline network that offers you more choice wherever your conferences take you, simply go to www.staralliance.com/conventionsplus

www.staralliance.com

Information correct as of 06/2013

SA_ConventionsPlus_AD_A4_2013-06_generic.indd 1 26.02.14 09:53 GASTROINTESTINAL TUMOURS

Saturday, 27 September 2014 Sunday, 28 September 2014 11:00/ EDUCATIONAL SESSION 08:00/ PATIENT CASES 12:30 Clinical impact of tumour biology in the management of 09:00 Challenges in oligometastatic disease: Ways towards oesophago-gastric cancer long-term survival of metastatic colorectal cancer Chair: Florian Lordick, Leipzig, Germany Co-Chairs: Theo Ruers, Amsterdam, Netherlands and Co-Chair: Fernando Rivera Herrero, Madrid, Spain Alberto Sobrero, Genoa, Italy Should locally advanced adenocarcinoma of the oesophagus and of Irresectable liver metastases: What do local ablative treatments the gastroesophageal junction (GEJ) be managed in the same way? contribute? Michael Stahl, Essen, Germany Theo Ruers, Amsterdam, Netherlands Surgery: Does response to preoperative therapy modify the What drives long-term survival with systemic treatment? extension of surgical resection? When is salvage surgery Alberto Sobrero, Genoa, Italy indicated? Discussion Arnulf Hölscher, Cologne, Germany Novel targets in the treatment of advanced gastric cancer: What 11:00/ EDUCATIONAL SESSION (REPETITION) exists already and what comes next? 12:30 A multidisciplinary approach to locoregionally Florian Lordick, Leipzig, Germany advanced rectal cancer Chair: Robert Glynne-Jones, Northwood, UK 14:15/ EDUCATIONAL SESSION Co-Chair: Eduardo Eduardo Diaz Rubio, Madrid, Spain 15:45 Optimising the treatment of colorectal cancer Radiotherapy: Which type and for whom? Chair: Richard Adams, Cardiff, UK Robert Glynne-Jones, Northwood, UK Co-Chair: to be announced Neoadjuvant and adjuvant chemotherapy: Is there a standard of Are there any useful tools when deciding about adjuvant care or not yet? chemotherapy? Andrés Cervantes, Valencia, Spain Richard Adams, Cardiff, UK Is there still room for improvement in surgery for locoregionally How to select first line chemotherapy in metastatic colorectal advanced rectal cancer? cancer Cornelis van de Velde, Leiden, Netherlands Claus-Henning Koehne, Oldenburg, Germany Optimising biomarkers based management beyond KRAS 14:15/ SPECIAL SYMPOSIUM Sabine Tejpar, Leuven, Belgium 15:45 Advances in precision medicine of metastatic colorectal cancer 16:00/ EDUCATIONAL SESSION Chair: Will Steward, Leicester, UK 17:30 A multidisciplinary approach to locoregionally Co-Chair: Thomas Seufferlein, Ulm, Germany advanced rectal cancer Introduction Chair: Robert Glynne-Jones, Northwood, UK Thomas Seufferlein, Ulm, Germany Co-Chair: Eduardo Diaz Rubio, Madrid, Spain New molecular classification of colorectal cancer Radiotherapy: Which type and for whom? Krisztian Homicsko, Lausanne, Switzerland Robert Glynne-Jones, Northwood, UK Emerging druggable targets in colorectal cancer Neoadjuvant and adjuvant chemotherapy: Is there a standard of Federica Di Nicolantonio, Candiolo, Italy care or not yet? Signal transduction inhibitors and pipeline drugs Andrés Cervantes, Valencia, Spain Josep Tabernero, Barcelona, Spain Is there still room for improvement in surgery for locoregionally advanced rectal cancer? Immunotherapy and vaccines Cornelis van de Velde, Leiden, Netherlands Pierpaolo Correale, Siena, Italy Liquid biopsies and “on treatment” markers Gerald Prager, Vienna, Austria Conclusions and clinical perspectives Will Steward, Leicester, UK

SCIENTIFIC COMMITTEE (COLORECTAL) Dirk Arnold, Freiburg, Germany, Chair Eduardo Díaz-Rubio, Madrid, Spain Gerald Prager, Vienna, Austria Federica Di Nicolantonio, Candiolo, Italy Thomas Seufferlein, Ulm, Germany Axel Grothey, Rochester, MN, USA Mattew Seymour, Leeds, UK Thomas Grünberger, Vienna, Austria Alberto Sobrero, Genoa, Italy Corrie Marijnen, Leiden, Netherlands Sabine Tejpar, Leuven, Belgium Per Pfeiffer, Odense, Denmark Christophe Tournigand, Créteil, France

16 Monday, 29 September 2014 10:30/ MULTIDISCIPLINARY INTERACTIVE SESSION (MIS) 14:15/ EDUCATIONAL SESSION (REPETITION) 11:30 Locally advanced pancreatic cancer 15:45 Optimising the treatment of colorectal cancer Chair: Eric Van Cutsem, Leuven, Belgium Chair: Richard Adams, Cardiff, UK Co-Chair: Bengt Glimelius, Uppsala, Sweden Co-Chair: to be announced Radiation oncology Are there any useful tools when deciding about adjuvant Bengt Glimelius, Uppsala, Sweden chemotherapy? Medical oncology Richard Adams, Cardiff, UK Eric Van Cutsem, Leuven, Belgium How to select first line chemotherapy in metastatic colorectal Discussion cancer Claus-Henning Koehne, Oldenburg, Germany 11:45/ MULTIDISCIPLINARY INTERACTIVE SESSION (MIS) Optimising biomarkers based management beyond KRAS 12:45 Sequence of treatment in colorectal cancer with Sabine Tejpar, Leuven, Belgium synchronous metastases Chair: Bernard Nordlinger, Boulogne, France 16:00/ SPECIAL SYMPOSIUM Co-Chair: Gunnar Folprecht, Dresden, Germany 17:30 Towards personalised medicine in gastric, pancreatic Surgery and liver cancer: From “omics” research to treatment Bernard Nordlinger, Boulogne, France Chair: Erika Martinelli, Naples, Italy Medical oncology Co-Chair: Michel Ducreux, Villejuif, France Gunnar Folprecht, Dresden, Germany Introduction Michel Ducreux, Villejuif, France Discussion What are the new tools available? 11:45/ PATIENT CASES Peter Schirrmacher, Heidelberg, Germany 12:45 Integrating systemic and locoregional therapies in a Hepatocellular carcinoma (HCC) patient with advanced hepatocellular carcinoma (HCC) Augusto Villanueva, London, UK Co-Chairs: Riccardo Lencioni, Pisa, Italy and Chris Verslype, Leuven, Belgium Pancreatic cancer Manuel Hidalgo, Madrid, Spain Systemic therapy Chris Verslype, Leuven, Belgium Gastric cancer Patrick Tan, Singapore Locoregional therapy Riccardo Lencioni, Pisa, Italy Conclusions and clinical perspectives Erika Martinelli, Naples, Italy Discussion 14:15 MULTIDISCIPLINARY INTERACTIVE SESSION (MIS) 15:15 Multidisciplinary management of peritoneal carcinomatosis Chair: Dominique Elias, Villejuif, France Co-Chair: Cornelis Punt, Amsterdam, Netherlands Surgery Dominique Elias, Villejuif, France Medical oncology Cornelis Punt, Amsterdam, Netherlands Discussion

SCIENTIFIC COMMITTEE (NON-COLORECTAL) Andrés Cervantes, Valencia, Spain, Chair Regina Beets-Tan, Maastricht, Netherlands Teresa Macarulla, Barcelona, Spain Fátima Carneiro, Porto, Portugal Erika Martinelli, Naples, Italy Thierry Conroy, Vandoeuvre-les-Nancy, France Fernando Rivera, Santander, Spain Michel Ducreux, Villejuif, France Juan Valle, Manchester, UK Karin Haustermans, Leuven, Belgium Chris Verslype, Leuven, Belgium Florian Lordick, Leipzig, Germany

Session timings may be subject to change within the same day 17 GENITOURINARY TUMOURS

Saturday, 27 September 2014 08:00/ CHALLENGE YOUR EXPERT (CYE) Sunday, 28 September 2014 09:00 Management of relapsed germ cell tumours 08:00/ CYE (REPETITION) Speaker: Joerg Beyer, Zurich, Switzerland 09:00 Management of relapsed germ cell tumours 08:00/ PATIENT CASES Speaker: Joerg Beyer, Zurich, Switzerland 09:00 Multimodal treatment approaches in bladder cancer 11:00/ EDUCATIONAL SESSION (REPETITION) Co-Chairs: Thierry Lebret, Suresnes, France; 12:30 Update in genitourinary oncology Nicholas James, Birmingham, UK and David Solit, New York, NY Chair: Bernard Escudier, Villejuif, France US Co-Chair: Ian Tannock, Toronto, ON, Canada The role of surgery in advanced bladder cancer Optimal sequence of treatment for metastatic prostate cancer Thierry Lebret, Suresnes, France Cora Sternberg, Rome, Italy Precision drug treatment for bladder cancer How to deal with unresectable and inoperable bladder cancer David Solit, New, York, NY, US Maria de Santis, Vienna, Ausria Is surgery always necessary? Treatment of metastatic renal cell carcinoma (RCC): Present and Nicholas James, Birmingham, UK future Discussion Bernard Escudier, Villejuif, France 14:00/ SPECIAL SYMPOSIUM 15:45 Precision medicine in prostate cancer Monday, 29 September 2014 Chair: Mark Rubin, New York, NY, US Co-Chair: Eleni Efstathiou, Athens, Greece 08:00/ PATIENT CASES Introduction 09:00 Treatment of castration-resistant prostate cancer Eleni Efstathiou, Athens, Greece (CRPC) in special situations Prostate carcinogenesis: What have we learnt from next Co-Chairs: Gerhardt Attard, Surrey, UK, generation sequencing? Anna Falanga, Bergamo, Italy and Stephane Oudard, Paris, France Levi A. Garraway, Boston, MA, US Treating elderly patients Stephane Oudard, Paris, France Do we need a new taxonomy for prostate cancer? Mark Rubin, New York, NY, US When is prostate cancer truly androgen independent? Gerhardt Attard, Surrey, UK Will circulating biomarkers help to deliver precision medicine? David Olmos, Madrid, Spain Bone marrow carcinosis and disseminated intravascular coagulation (DIC) Immunotherapy for prostate cancer? Anna Falanga, Bergamo, Italy Charles Drake, Baltimore, MD, US Discussion Where next for precision medicine for prostate cancer? Eleni Efstathiou, Athens, Greece 09:15/ SPECIAL SYMPOSIUM Conclusions and clinical perspectives 10:45 Beyond tumour heterogeneity: New pathways in kidney Mark Rubin, New York, NY, US cancer Chair: Viktor Grünwald, Hannover, Germany 16:00/ EDUCATIONAL SESSION Co-Chair: Cora Sternberg, Rome, Italy 17:30 Update in genitourinary oncology Introduction Chair: Bernard Escudier, Villejuif, France Cora Sternberg, Rome, Italy Co-Chair: Ian Tannock, Toronto, ON, Canada Molecular classification of kidney cancer Optimal sequence of treatment for metastatic prostate cancer Andrew Futreal, Houston, TX, US Cora Sternberg, Rome, Italy Precision medicine in kidney cancer and clinical trial designs How to deal with unresectable and inoperable bladder cancer James Larkin, London, UK Maria de Santis, Vienna, Autria Immunotherapy: Myth or reality? Treatment of metastatic renal cell carcinoma (RCC): Present and David McDermott, Boston, MA, US future Bernard Escudier, Villejuif, France New drugs and new targets (phase I) Emiliano Calvo, Madrid, Spain Conclusions and clinical perspectives Viktor Grünwald, Hannover, Germany

18 Session timings may be subject to change within the same day SCIENTIFIC COMMITTEE (PROSTATE) Eleni Efstathiou, Athens, Greece, Chair Gerhardt Attard, Sutton, UK Chris Parker, Sutton, UK Karim Fizazi, Villejuif, France Mark Rubin, New York, NY, US Silke Gillessen, St. Gallen, Switzerland Jack Schalken, Nijmegen, Netherlands Axel Heidenreich, Aachen, Germany Avishay Sella, Zerifin, Israel David Olmos, Madrid, Spain Anders Widmark, Umeå, Sweden Stephane Oudard, Paris, France

SCIENTIFIC COMMITTEE (NON-PROSTATE) James Larkin, London, UK, Chair Michael Aitchison, Glasgow, UK Nicholas James, Birmingham, UK Axel Bex, Amsterdam, Netherlands Arnaud Mejean, Paris, France Emiliano Calvo, Madrid, Spain Gerald Mickisch, Bremen, Germany Maria De Santis, Vienna, Austria Manuela Schmidinger, Vienna, Austria Bernard Escudier, Villejuif, France Cora Sternberg, Rome, Italy Viktor Grünwald, Hannover, Germany

19 GYNAECOLOGICAL CANCERS

Saturday, 27 September 2014 08:00/ CHALLENGE YOUR EXPERT (CYE) 14:15/ EDUCATIONAL SESSION (REPETITION) 09:00 Medical treatment for advanced endometrial cancer 15:45 Ovarian cancer Speaker: Cristiana Sessa, Bellinzona, Switzerland Chair: Antonio Gonzalez Martin, Madrid, Spain Co-Chair: Nicoletta Colombo, Milan, Italy 14:15/ EDUCATIONAL SESSION Antiangiogenic therapy: Where in the disease pathway and which 15:45 Ovarian cancer patients? Chair: Antonio Gonzalez Martin, Madrid, Spain Antonio Gonzalez Martin, Madrid, Spain Co-Chair: Nicoletta Colombo, Milan, Italy How to recognise and treat low grade tumours Antiangiogenic therapy: Where in the disease pathway and which Jonathan Ledermann, London, UK patients? Antonio Gonzalez Martin, Madrid, Spain Treatment for relapsing patients Sandro Pignata, Naples, Italy How to recognise and treat low grade tumours Jonathan Ledermann, London, UK Treatment for relapsing patients Monday, 29 September 2014 Sandro Pignata, Naples, Italy 08:00/ PATIENT CASES 09:00 Primary surgery or neoadjuvant chemotherapy for Sunday, 28 September 2014 ovarian cancer: How should we select the patients? Co-Chairs: Charles Gourley, Edinburgh, UK; 08:00/ CYE (REPETITION) Christian Marth, Innsbruck, Austria and 09:00 Medical treatment for advanced endometrial cancer Isabelle Ray-Coquard, Lyon, France Speaker: Cristiana Sessa, Bellinzona, Switzerland The role of upfront surgery Christian Marth, Innsbruck, Austria 09:30/ MULTIDISCIPLINARY INTERACTIVE SESSION (MIS) Best neo-adjuvant therapy: Options for selected patients 10:30 Management of localised endometrial cancer Isabelle Ray-Coquard, Lyon, France Chair: Carien L. Creutzberg, Leiden, Netherlands Co-Chair: Mansoor Mirza, Copenhagen, Denmark Is there a molecular analysis that can help us define a subgroup Radiotherapy of patients? Carien L. Creutzberg, Leiden, Netherlands Charles Gourley, Edinburgh, UK Clinical oncology Discussion Mansoor Mirza, Copenhagen, Denmark Discussion 11:00/ SPECIAL SYMPOSIUM 12:30 Targeted therapy in gynaecological cancer Chair: Andres Poveda, Valencia, Spain Co-Chair: Eric Pujade-Lauraine, Paris, France Introduction Eric Pujade-Lauraine, Paris, France Emerging molecular targets in gynaecological cancer David Huntsman, Vancouver, BC, Canada The impact of targeted therapy in cervical and endometrial cancer Ana Oaknin, Barcelona, Spain Targeted therapy of ovarian cancer: Beyond angiogenesis Nicoletta Colombo, Milan, Italy The coming decade Michael Bookman, Tucson, AZ, US Conclusions and clinical perspectives Andres Poveda, Valencia, Spain SCIENTIFIC COMMITTEE Andres Poveda, Valencia, Spain, Chair Michael Bookman, Tucson, AZ, US José Palacios Calvo, Madrid, Spain Antonio González Martin, Madrid, Spain Timothy Perren, Leeds, UK Philipp Harter, Essen, Germany Sandro Pignata, Naples, Italy Jonathan Ledermann, London, UK Eric Pujade-Lauraine, Paris, France Christian Marth, Innsbruck, Austria Isabelle Ray-Coquard, Lyon, France Mansoor Mirza, Copenhagen, Denmark

20 Session timings may be subject to change within the same day HAEMATOLOGICAL MALIGNANCIES

Saturday, 27 September 2014 Monday, 29 September 2014 14:15/ SPECIAL SYMPOSIUM 09:15/ PATIENT CASES 15:45 Targeting signalling pathways in haematological 10:15 Imaging decisions in haematological malignancies malignancies: Are we close to the end of histopathological Co-Chairs: Josee Zijlstra, Amsterdam, Netherlands and classification and the chemotherapy era? Christina Messiou, Surrey, UK Chair: Andreas Rosenwald, Würzburg, Germany Lymphoma: What to do and when? Co-Chair: Faith Davies, Sutton, UK Josee Zijlstra, Amsterdam, Netherlands Introduction: Is a purely biological classification of lymphoma Myeloma: What to do and when? possible? Christina Messiou, Surrey, UK Faith Davies, Sutton, UK Discussion Targeting kinases and relevance in B-cell lymphomas (BCL) Ingo Ringshausen, Munich, Germany 11:00/ JOINT SYMPOSIUM: ESMO - EANM Targeting the BCL-2 pathway 12:30 Impact of molecular imaging on management of Anthony Letai, Boston, MA, US lymphoma Co-Chairs: Michele Ghielmini, Bellinzona, Switzerland and Targeting the cyclins Wim Oyen, Nijmegen, Netherlands Paolo Ghia, Milan, Italy Introduction Translating genetics into clinical care Wim Oyen, Nijmegen, Netherlands Thorsten Zenz, Heidelberg, Germany PET-based decisions in Hodgkin’s lymphoma Conclusions: Is this the end of chemotherapy in lymphoma? Martin Hutchings, Copenhagen, Denmark Andreas Rosenwald, Würzburg, Germany PET-based decisions in non Hodgkin’s lymphoma Josee Zijlstra, Amsterdam, Netherlands Potential and pitfalls in PET-imaging of lymphoma To be announced PET-based response criteria in lymphoma : Current status and future directions Michel Meignan, Créteil, France Conclusions Michele Ghielmini, Bellinzona, Switzerland 16:00/ EDUCATIONAL SESSION 17:30 Major lymphoma subtypes in the elderly Chair: Martin Dreyling, Munich, Germany Co-Chair: Michele Ghielmini, Bellinzona, Switzerland Diffuse large cell lymphoma: 8x R-CHOP 21: Is there one standard therapy for all patients? Peter Johnson, Southampton, UK Follicular lymphoma: Is it a boring disease? Martin Dreyling, Munich, Germany Chronic lymphocytic leukemia (CLL): Is treatment the same as in younger patients? Michael Hallek, Cologne, Germany

SCIENTIFIC COMMITTEE Faith Davies, Sutton, UK, Chair Peter Campbell, Cambridge, UK Ingo Ringshausen, Munich, Germany Enrico Derenzini, New York, NY, US Andreas Rosenwald, Wuerzburg, Germany Paolo Ghia, Milan, Italy Evangelos Terpos, Athens, Greece Enrico Ocio, Salamanca, Spain Elena Zamagni, Bologna, Italy Gert Ossenkooppele, Amsterdam, Netherlands Thorsten Zenz, Heidelberg, Germany Mariano Provencio, Madrid, Spain

Session timings may be subject to change within the same day 21 HEAD AND NECK CANCER

Saturday, 27 September 2014 Sunday, 28 September 2014 08:00/ CHALLENGE YOUR EXPERT (CYE) 08:00/ CYE (REPETITION) 09:00 Larynx preservation: How should we decide the best 09:00 Larynx preservation: How should we decide the best treatment? treatment? Speaker: Jean-Louis Lefebvre, Lille, France Speaker: Jean-Louis Lefebvre, Lille, France 11:00/ SPECIAL SYMPOSIUM 11:00/ MULTIDISCIPLINARY INTERACTIVE SESSION (MIS) 12:30 Personalised medicine in head and neck cancer 12:00 Locally advanced nasopharyngeal carcinoma Chair: Sandrine Faivre, Clichy, France Chair: Lisa Licitra, Milan, Italy Co-Chair: Juan J. Grau, Barcelona, Spain Co-Chair: Jean Bourhis, Lausanne, Switzerland Introduction Medical oncology Juan J. Grau, Barcelona, Spain Lisa Licitra, Milan, Italy New targets in squamous cell carcinoma Radiotherapy Jean-Pascal Machiels, Brussels, Belgium Jean Bourhis, Lausanne, Switzerland New targets in salivary gland cancer Discussion Andrew Futreal, Houston, TX, US 14:30/ PATIENT CASES Immunotherapy for head and neck cancer 15:30 Treatment of medullary thyroid cancer (MTC) Erik Hooijberg, Amsterdam, Netherlands Co-Chairs: Jaume Capdevila, Barcelona, Spain and Next generation technology for next generation trials Sophie Leboulleux, Villejuif, France Christophe Le Tourneau, Paris, France Sub-classification and treatment of MTC Conclusion and clinical perspectives Sophie Leboulleux, Villejuif, France Sandrine Faivre, Clichy, France Practical management of tyrosine-kinase inhibitor (TKI) Jaume Capdevila, Barcelona, Spain Discussion

SCIENTIFIC COMMITTEE Sandrine Faivre, Clichy, France, Chair Jean Bourhis, Lausanne, Switzerland Gabriela Kornek, Vienna, Austria Andreas Dietz, Leipzig, Germany Christophe Le Tourneau, Paris, France Cai Grau, Aarhus, Denmark Lisa Licitra, Milan, Italy Juan José Grau, Barcelona, Spain Jean-Pascal Machiels, Brussels, Belgium Kevin Harrington, London, UK Amanda Psyrri, Athens, Greece Florence Huguet, Paris, France

22 Session timings may be subject to change within the same day IMMUNOTHERAPY OF CANCER

Saturday, 27 September 2014 11:00/ JOINT SYMPOSIUM: ESMO - ESP 16:00/ EDUCATIONAL SESSION 12:30 Tissue markers for immuno-oncology 17:30 Fundamental principles of cancer immunotherapy: Co-Chairs: Fatima Carneiro, Porto, Portugal and What the clinician needs to know Fortunato Ciardiello, Naples, Italy Chair: Suzy Scholl, Paris, France Introduction Co-Chair: Ulrich Keilholz, Berlin, Germany Fortunato Ciardiello, Naples, Italy Fundamental principles of antitumour immune response: A The importance of the preanalytical phase (the proper handling summary for the clinician of specimens from site of biopsy to pathology lab, fixation etc) for Suzy Scholl, Paris, France immunohistochemistry Fundamental mechanisms of tumour immune evasion: A To be announced summary for the clinician How to quantify immuohistochemical slides Sjoerd van der Burg, Leiden, Netherlands To be announced How therapeutic immunomodulation can restore antitumour Importance of external quality assessement in immuno-oncology immunity: From theory to practice To be announced Mario Sznol, New Haven, CT, US What the oncologist needs from the pathologist To be announced Monday, 29 September 2014 Conclusions Fatima Carneiro, Porto, Portugal 09:00/ SPECIAL SYMPOSIUM 10:30 Activating immune response to cancer 13:00/ KEYNOTE LECTURE Chair: Michele Maio, Siena, Italy 13:45 Delivering precision immunotherapy Co-Chair: Suzy Scholl, Paris, France Chair: George Coukos, Lausanne, Switzerland Introduction Speaker: Carl June, Philadelphia, PA, US Suzy Scholl, Paris, France Tumour infiltrating lymphocytes (TIL) and their use in therapy Sunday, 28 September 2014 Inge Marie Svane, Herlev, Danmark Adoptive therapy with engineered T-cells 14:15/ SPECIAL SESSION Carl June, Philadelphia, PA, US 15:45 Evasion, activation and manipulation of the cancer New developments in clinical vaccinations immuno response Ulrich Keilholz, Berlin, Germany Chair: Sjoerd van der Burg, Leiden, Netherlands Rational combinations in cancer immunotherapy Co-Chair: Inge Marie Svane, Herlev, Denmark Ignacio Melero, Pamplona, Spain Introduction Sjoerd van der Burg, Leiden, Netherlands Conclusions and clinical perspectives Michele Maio, Siena, Italy Overcoming immune evasion Daniel Speiser, Lausanne, Switzerland 14:30/ PATIENT CASES Precision medicine in immunotherapy 15:30 Immunotherapy in clinical practice George Coukos, Lausanne, Switzerland Co-Chairs: Antoni Ribas, Los Angeles, CA, US and Dirk Schadendorf, Essen, Germany Building rational combinations in immunotherapy Michele Maio, Siena, Italy Challenges in the assessment of response to cancer immunotherapy Clinical interpretation of response with immunotherapy Antoni Ribas, Los Angeles, CA, US John Haanen, Amsterdam, Netherlands Management of toxicity during immunotherapy Conclusions and clinical perspectives Dirk Schadendorf, Essen, Germany Inge Marie Svane, Herlev, Denmark Discussion

SCIENTIFIC COMMITTEE George Coukos, Lausanne, Switzerland, Chair Hinrich Abken, Cologne, Germany Michele Maio, Siena, Italy Luis de la Cruz Merino, Seville, Spain Ignacio Melero, Pamplona, Spain John Haanen, Amsterdam, Netherlands Suzy Scholl, Paris, France Robert Hawkins, Manchester, UK Inge-Marie Svane, Copenhagen, Denmark Ulrich Keilholz, Berlin, Germany Sjoerd van der Burg, Leiden, Netherlands

Session timings may be subject to change within the same day 23 LUNG CANCER AND OTHER THORACIC MALIGNANCIES

Saturday, 27 September 2014 Sunday, 28 September 2014 08:00/ PATIENT CASES 09:00/ EDUCATIONAL SESSION (REPETITION) 09:00 Therapeutic challenges in oncogene addicted lung 10:30 Systemic treatment of metastatic NSCLC cancers Chair: Benjamin Besse, Villejuif, France Co-Chairs: Silvia Novello, Orbassano, Italy and Co-Chair: Lucio Crinò, Perugia, Italy Ken O’Byrne, Brisbane, Australia Non-oncogenic addicted NSCLC patients: What is the best A case of EGFR mutation in squamous cell carcinoma approach? Silvia Novello, Orbassano, Italy Benjamin Besse, Villejuif, France A ROS1 translocated NSCLC patient Oncogenesis addiction, biomarkers: Who should be tested and Ken O’Byrne, Brisbane, Australia when? Discussion Pasi Jånne, Boston, MA, US How do we define progression and what is to be done? 09:15/ EDUCATIONAL SESSION Anne-Marie Dingemans, Maastricht, Netherlands 10:45 Systemic treatment of metastatic NSCLC Chair: Benjamin Besse, Villejuif, France 11:00/ EDUCATIONAL SESSION (REPETITION) Co-Chair: Lucio Crinò, Perugia, Italy 12:30 Clinical issues in metastatic NSCLC Non-oncogenic addicted NSCLC patients: What is the best Chair: Tony S.K. Mok, Hong Kong, China approach? Co-Chair: Jean-Yves Douillard, St. Herblain, France Benjamin Besse, Villejuif, France Is there anything new in squamous cells? Oncogenesis addiction, biomarkers: Who should be tested and Wilfried Eberhardt, Essen, Germany when? The best approach to oligometastatic NSCLC Pasi Jånne, Boston, MA, US Jaroslaw Kuzdzal, Krakow, Poland How do we define progression and what is to be done? Optimal sequence of administration for targeted agents Anne-Marie Dingemans, Maastricht, Netherlands and chemotherapy Tony S.K. Mok, Hong Kong, China 11:00/ EDUCATIONAL SESSION 12:30 Clinical issues in metastatic NSCLC 14:15/ MULTIDISCIPLINARY INTERACTIVE SESSION (MIS) Chair: Tony S.K. Mok, Hong Kong, China 15:15 Management of brain metastasis: Surgery vs radiation Co-Chair: Jean-Yves Douillard, St.Herblain, France vs late intervention Is there anything new in squamous cells? Chair: Dirk De Ruysscher, Leuven, Belgium Wilfried Eberhardt, Essen, Germany Co-Chair: Lucio Crinò, Perugia, Italy The best approach to oligometastatic NSCLC Medical oncology Jaroslaw Kuzdzal, Krakow, Poland Lucio Crinò, Perugia, Italy Optimal sequence of administration for targeted agents Radiotherapy and chemotherapy Dirk De Ruysscher, Leuven, Belgium Tony S.K. Mok, Hong Kong, China Discussion 14:30/ PATIENT CASES 15:30 Challenging cases of oligometastatic NSCLC Co-Chairs: Umberto Ricardi, Turin, Italy and Michael Thomas, Ulm, Germany An EGFR mutated patient with a right/left -sided located T3N0 non-squamous cell lung cancer and a solitary right/left adrenal gland metastasis Michael Thomas, Ulm, Germany A patient with a right upper lobe peripherally located T1b adenocarcinoma with a bone metastasis in the left rib 9 and in dorsal vertebra 4 Umberto Ricardi, Turin, Italy Discussion SCIENTIFIC COMMITTEE (NSCLC, EARLY STAGE, SCLC AND OTHER THORACIC MALIGNANCIES) Johan Vansteenkiste, Leuven, Belgium, Chair Benjamin Besse, Villejuif, France Gaetano Rocco, Naples, Italy Dirk De Ruysscher, Leuven, Belgium Giorgio Scagliotti, Orbassano, Italy Wilfried Eberhardt, Essen, Germany Philipp Schnabel, Heidelberg, Germany Eric Lim, London, UK Suresh Senan, Amsterdam, Netherlands Celine Mascaux, Toronto, ON, Canada Giulia Veronesi, Milan, Italy Tetsuya Mitsudomi, Osaka-Sayama, Japan

24 Monday, 29 September 2014 Tuesday, 30 September 2014 08:00/ CHALLENGE YOUR EXPERT (CYE) 08:00/ CYE (REPETITION) 09:00 SCLC: Current approaches and the role of radiotherapy 09:00 SCLC: Current approaches and the role of radiotherapy (thoracic and PCI) in stage IV disease (thoracic and PCI) in stage IV disease Speaker: Thierry Le Chevalier, Villejuif, France Speaker: Thierry Le Chevalier, Villejuif, France 09:00/ SPECIAL SYMPOSIUM 10:30 The evolving role of systemic treatment in advanced NSCLC Chair: Jean-Charles Soria, Villejuif, France Co-Chair: Ken O’Byrne, Brisbane, Australia Introduction Ken O’Byrne, Brisbane, Australia Reclassifying lung cancer and molecular diagnostic Ramaswamy Govindan, St. Louis, MO, US Targeting tumour addiction Rafal Dziadziuszko, Gdansk, Poland Secondary resistance to systemic treatment Egbert Smit, Amsterdam, Netherlands Immunotherapy: Current status Martin Reck, Grosshansdorf, Germany Conclusions and clinical perspectives Jean-Charles Soria, Villejuif, France 16:00/ SPECIAL SYMPOSIUM 17:30 Diagnostic and therapeutic challenges in thoracic malignancies Chair: Johan Vansteenkiste, Leuven, Belgium Co-Chair: Suresh Senan, Amsterdam, Netherlands Introduction Suresh Senan, Amsterdam, Netherlands Optimal assessment of an additional lung nodule in a patient with potential for cure Christophe Dooms, Leuven, Belgium What is the place of less invasive surgery in lung cancer? Giulia Veronesi, Milan, Italy Stereotactic ablative radiotherapy in early stage NSCLC Suresh Senan, Amsterdam, Netherlands Defining the role of targeted therapies in early stage NSCLC Solange Peters, Lausanne, Switzerland Conclusions and clinical perspectives Johan Vansteenkiste, Leuven, Belgium

SCIENTIFIC COMMITTEE (NSCLC, METASTATIC) Solange Peters, Lausanne, Switzerland, Chair Alex A. Adjei, Buffalo, NY, US Ken O’Byrne, Brisbane, Australia Lucio Crinò, Perugia, Italy Martin Reck, Grosshansdorf, Germany Rafal Dziadziuszko, Gdansk, Poland Rafael Rosell, Badalona, Spain Keith Kerr, Aberdeen, UK Egbert Smit, Amsterdam, Netherlands Tony S.K. Mok, Hong Kong, China James Spicer, London, UK Silvia Novello, Orbassano, Italy

Session timings may be subject to change within the same day 25 MELANOMA AND OTHER SKIN TUMOURS

Saturday, 27 September 2014 09:15/ PATIENT CASES 16:00/ SPECIAL SYMPOSIUM 10:15 Immunotherapy or targeted therapy for oncogene 17:30 The science behind combinations with immunotherapy addicted melanoma in melanoma Co-Chairs: Anna Maria Di Giacomo, Siena, Itlay and Chair: John Haanen, Amsterdam, Netherlands James Larkin, London, UK Co-Chair: Christian Blank, Amsterdam, Netherlands Choice of immunotherapy vs targeted therapy in first line (BRAF) Introduction James Larkin, London, UK Christian Blank, Amsterdam, Netherlands Oncogene addicted brain metastases The tumour microenvironment as a barrier for immune Anna Maria Di Giacomo, Siena, Italy destruction of cancer Discussion Jürgen Becker, Graz, Austria Rationale to combine immunotherapy with physical therapy 11:00/ EDUCATIONAL SESSION Kevin Harrington, London, UK 12:30 Skin tumours update Chair: Jürgen Becker, Graz, Austria Which systemic therapies should be combined to Co-Chair: to be announced immunotherapy? Merkel cell carcinoma Christian Blank, Amsterdam, Netherlands Jürgen Becker, Graz, Austria Combining immunotherapies Adjuvant treatment of melanoma Antoni Ribas, Los Angeles, CA, US Olivier Michielin, Lausanne, Switzerland Conclusions and clinical perspectives Targeted therapy and immunotherapy for melanoma John Haanen, Amsterdam, Netherlands David Solit, New York, NY, US

SCIENTIFIC COMMITTEE Caroline Robert, Villejuif, France, Chair Paolo Ascierto, Naples, Italy Richard Marais, Manchester, UK Jurgen Becker, Graz, Austria Grant McArthur,Melbourne, Australia Christian Blank, Amsterdam, Netherlands Olivier Michielin, Lausanne, Switzerland Reinhard Dummer, Zurich, Switzerland Mark Middleton, Oxford, UK Jean-Jacques Grob, Marseille, France Antoni Ribas, Los Angeles, CA, US José Antonio López Martín, Madrid, Spain

26 Session timings may be subject to change within the same day NETs AND ENDOCRINE TUMOURS

Sunday,28 September 2014 Monday, 29 September 2014 10:30/ PATIENT CASES 11:00/ EDUCATIONAL SESSION 11:30 How does one manage rare neuroendocrine 12:30 Update on all neuroendocrine tumours malignancies? Chair: Ian Chau, Sutton, UK Co-Chairs: Piero Ferolla, Perugia, Italy and Co-Chair: Alfredo Carrato, Madrid, Spain Alexandria Phan, Houston, TX, US Classification and tumour biology Malignant bronchial carcinoid tumour Kjell Öberg, Uppsala, Sweden Piero Ferolla, Perugia, Italy Molecular imaging and peptide receptor radionuclide therapy Paraganglioma (PRRT) Alexandria Phan, Houston, TX, US Lisa Bodei, Milan, Italy Discussion Classical and targeted therapies in GEP-NETs Ian Chau, Sutton, UK 16:00/ SPECIAL SYMPOSIUM 17:30 Neuroendocrine tumours: The cutting edge and a glimpse into the future Chair: Ian Chau, Sutton, UK Co-Chair: Philippe Ruszniewski, Clichy, France Introduction Philippe Ruszniewski, Clichy, France Towards new molecular classification for neuroendocrine tumours Aldo Scarpa, Verona, Italy Tools to evaluate tumour response to therapy: Imaging Marie-Pierre Vullierme, Clichy, France Tools to evaluate tumour response to therapy: Tissue biomarkers Tim Meyer, London, UK Do minimal access and robotic surgery bring benefit to neuroendocrine tumours? Massimo Falconi, Ancona, Italy Current landscape and ongoing clinical trials for medical therapy in neuroendocrine tumours Marianne Pavel, Berlin, Germany Clinical trial endpoints relevant to patients/society for rare tumours and conclusions Ian Chau, Sutton, UK

SCIENTIFIC COMMITTEE Ian Chau, Sutton, UK, Chair Massimo Falconi, Ancona, Italy Marianne Pavel, Berlin, Germany Ashley Grossman, Headington, UK Alexandria Phan, Houston, TX, US Dik Kwekkeboom, Rotterdam, Netherlands Guido Rindi, Rome, Italy Steven Libutti, New York, NY, US Philippe Ruszniewski, Clichy, France Kjell Öberg, Uppsala, Sweden Britt Skogseid, Uppsala, Sweden

Session timings may be subject to change within the same day 27 PUBLIC HEALTH AND HEALTH ECONOMICS

Saturday, 27 September 2014 Monday, 29 September 2014 16:00/ PATIENT CASES 14:15/ SPECIAL SYMPOSIUM 17:00 Avoiding overdiagnosis and overtreatment in cancer 15:45 The impact on health services from personalised screening: Assessing the role of personalised targeted therapies screening Chair: Josep M. Borras, Barcelona, Spain Co-Chairs: Harry de Koning, Rotterdam, Netherlands; Co-Chair: Tit Albreht, Ljubljana, Slovenia Silvia de Sanjose, L'Hospitalet de Llobregat, Spain and Introduction Nereo Segnan, Turin, Italy Tit Albreht, Ljubljana, Slovenia Precision medicine in cancer prevention: From genomic to Confronting health services: Targeting the baby boom stratified, population based cancer screening Valery Lemmens, Eindhoven, Netherlands Nereo Segnan, Turin, Italy Budget impact vs cost effectiveness: Implications for Personalised versus organised approaches to screening of personalised cancer therapies cervical cancer: Can we fit both? Yolande Lievens, Ghent, Belgium Silvia de Sanjose, L'Hospitalet de Llobregat, Spain Evolution of pricing and reimbursement structure of cancer Pulmonary nodules and CT-lung cancer screening therapies in Europe Harry de Koning, Rotterdam, Netherlands Richard Sullivan, London, UK Discussion Personalised medicine in National Cancer Plans: How can innovation be translated into policy? Jose Maria Martin Moreno, Valencia, Spain Conclusions and clinical perspectives Josep M. Borras, Barcelona, Spain

SCIENTIFIC COMMITTEE Josep Maria Borras, Barcelona, Spain, Chair Tit Albreht, Ljubljana, Slovenia Silvano Gallus, Milan, Italy Freddie Bray, Lyon, France Valery Lemmens, Eindhoven, Netherlands Jack Cuzick, London, UK Yolande Lievens, Ghent, Belgium Harry de Koning, Rotterdam, Netherlands Jose M. Martin-Moreno, Valencia, Spain Sivia de Sanjosé, L’Hospitalet de Llobregat, Spain Nereo Segnan, Turin, Italy

28 Session timings may be subject to change within the same day SARCOMA

Saturday, 27 September 2014 Monday, 29 September 2014 09:00/ EDUCATIONAL SESSION 11:00/ SPECIAL SYMPOSIUM 10:30 Biology must guide the treatment in sarcoma 12:30 Controversies in the neo-adjuvant treatment of Chair: Silvia Stacchiotti, Milan, Italy localised soft tissue sarcomas (STS) Co-Chair: Jean-Yves Blay, Lyon, France Chair: Alessandro Gronchi, Milan, Italy Sarcoma pathology for clinicians Co-Chair: Stefan Sleijfer, Rotterdam, Netherlands A. Paolo dei Tos, Treviso, Italy Introduction: Induction therapy in localised STS: For whom Could medical treatment be histology guided? and with what? Silvia Stacchiotti, Milan, Italy Stefan Sleijfer, Rotterdam, Netherlands Gastrointestinal stromal tumours (GIST) Evolving biology of sarcoma Sebastian Bauer, Essen, Germany Jean-Yves Blay, Lyon, France Is there a role for neo-adjuvant systemic treatment in STS? Javier Martin Broto, Palma de Mallorca, Spain Sunday, 28 September 2014 Innovative combination of targeted agents with radiotherapy 16:00/ PATIENT CASES Rick Haas, Amsterdam, Netherlands 17:00 The management of isolated lung metastases from Local treatment after neo-adjuvant therapy soft tissue sarcomas (STS) Piotr Rutkowski, Warsaw, Poland Co-Chairs: Axel Le Cesne, Villejuif, France; Conclusions and clinical perspectives Aisha Miah, London, UK and Ugo Pastorino, Milan, Italy Alessandro Gronchi, Milan, Italy Surgery: Why and when? Ugo Pastorino, Milan, Italy Systemic treatment for a patient with isolated lung metastases: What is the current standard? Axel Le Cesne, Villejuif, France The sense and non-sense of radiotherapy and radiofrequency ablation to control isolated lung metastases Aisha Miah, London, UK Discussion

SCIENTIFIC COMMITTEE Stefan Sleijfer, Rotterdam, Netherlands, Chair Thomas Brodowicz, Vienna, Austria Aisha Miah, London, UK Robin Jones, Seattle, WA, US Nicolas Penel, Lille, France Bernd Kasper, Mannheim, Germany Piotr Rutkowski, Warsaw, Poland Axel Le Cesne, Villejuif, France Winette van der Graaf, Nijmegen, Netherlands Cecile Le Pechoux, Villejuif, France Kees Verhoef, Rotterdam, Netherlands Javier Martin Broto, Palma de Mallorca, Spain

Session timings may be subject to change within the same day 29 SUPPORTIVE AND PALLIATIVE CARE

Saturday, 27 September 2014 Monday, 29 September 2014 09:15/ EDUCATIONAL SESSION 08:00/ CHALLENGE YOUR EXPERT (CYE) 10:45 Symptoms in oncology 09:00 Thromboembolic disorders in oncology: Present status Chair: Carla Ripamonti, Milan, Italy and novel agents Co-Chair: Florian Strasser, St. Gallen, Switzerland Speaker: Mario Dicato, Luxembourg Organ toxicities from targeted therapies Carla Ripamonti, Milan, Italy Metabolic disorders Tuesday, 30 September 2014 Viktor Grünwald, Hannover, Germany 08:00/ CYE (REPETITION) Complications arising with compliances 09:00 Thromboembolic disorders in oncology: Present status Andrea Antonuzzo, Pisa, Italy and novel agents 11:45/ PATIENT CASES Speaker: Mario Dicato, Luxembourg 12:45 Pregnancy and fertility preservation in patients with cancer Co-Chairs: Hatem A. Azim, Brussels, Belgium and Hamish Wallace, Edinburgh, UK How to manage a pregnant woman with cancer Hatem A. Azim, Brussels, Belgium Fertility preservation in the cancer patient Hamish Wallace, Edinburgh, UK Discussion 15:55/ SPECIAL SYMPOSIUM 17:30 Targeting precision medicine toxicity Chair: Mario Dicato, Luxembourg Co-Chair: Fausto Roila, Terni, Italy Introduction Mario Dicato, Luxembourg Cardiac toxicity Lillian Siu, Toronto, ON, Canada Pulmonary toxicity Guy Meyer, Paris, France Skin toxicity Caroline Robert, Villejuif, France Endocrine toxicity Fausto Roila, Terni, Italy Osteoarticular toxicity Ignacio Tusquets, Barcelona, Spain GI toxicity Jervoise Andreyev, London, UK

SCIENTIFIC COMMITTEE Mario Dicato, Luxembourg, Chair Raphael Catane, Tel Hashomer, Israel Carla Ripamonti, Milan, Italy Petra Feyer, Berlin, Germany César Rodriguez, Salamanca, Spain Pere Gascon, Barcelona, Spain Fausto Roila, Terni, Italy Joern Herrstedt, Odense, Denmark Florian Scotté, Paris, France Ivan Krakowski, Vandoeuvre-les-Nancy, France Simon Van Belle, Ghent, Belgium Alex Molasiotis, Hong Kong, China

30 Session timings may be subject to change within the same day GENERAL INTEREST

Friday, 26 September 2014 Saturday, 27 September 2014 12:00/ ESMO 2014 Opening Session 08:00/ CHALLENGE YOUR EXPERT (CYE) 13:15 09:00 Is hormone therapy really harmless in elderly people? ESMO Presidential Address Speaker: Matti Aapro, Genolier, Switzerland Rolf A. Stahel, Zurich, Switzerland 11:00/ SPECIAL SESSION -ESMO COMMUNITY ONCOLOGY Presentation of the ESMO Award by 12:30 WORKING GROUP (COWG) Josep Tabernero, Barcelona, Spain Optimal use of systemic therapy in the palliative setting ESMO Award lecture Chair: Robert Eckert, Wendlingen, Germany To be announced Co-Chair: Michalis Karamouzis, Athens, Greece Presentation of the ESMO Hamilton Fairley Award by The who and where of cancer care in Europe: Insights from Josep Tabernero, Barcelona, Spain a community oncology survey among ESMO National ESMO Hamilton Fairley Award lecture Representatives To be announced Robert Eckert, Wendlingen, Germany Presentation of the ESMO Lifetime Achievement Award by When to start systemic therapy: Indications for initiation of Josep Tabernero, Barcelona, Spain chemotherapy vs watchful waiting Ian Tannock, Toronto, ON, Canada ESMO Lifetime Achievement Award lecture To be announced Have a (systemic therapy) break: Optimal duration of systemic therapy in common tumours ESMO 2014 Scientific Address Richard Herrmann, Basel, Switzerland Johann S. de Bono, Sutton, UK Trials and tribulations: Lifetime experiences of a medical Welcome reception oncologist on chemotherapy intensification To be announced It’s time to stop: When to initiate palliative / supportive therapy Sofia Braga, Lisbon, Portugal Conclusions Michalis Karamouzis, Athens, Greece 14:15/ JOINT SYMPOSIUM: ESMO EMERGING COUNTRIES 15:45 COMMITTEE (ECC) - AORTIC-SLACOM-UICC-WHO Personalised cancer care in countries with limited resources Details to be announced 16:00/ SPECIAL SESSION 17:30 Liquid biopsy: Monitoring tumour-derived cell-free DNA, circulating tumour cells (CTC) and exosomes in patients with solid tumours Chair: Alberto Bardelli, Turin, Italy Co-Chair: Carlos Caldas, Cambridge, UK Introduction Carlos Caldas, Cambridge, UK Clinical applications for microRNAs in lung cancer Carlo Croce, Columbus, OH, US Circulating tumour cells: Isolation, enrichment and clinical value in breast cancer Michail Ignatiadis, Brussels, Belgium Liquid biopsies: Genotyping circulating tumour DNA in colorectal cancer Alberto Bardelli, Turin, Italy The potential of circulating tumour cells as a liquid biopsy to guide therapy in prostate cancer Klaus Pantel, Hamburg, Germany Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA Carlos Caldas, Cambridge, UK Conclusions and clinical perspectives Alberto Bardelli, Turin, Italy

Session timings may be subject to change within the same day 31 GENERAL INTEREST

Sunday, 28 September 2014 08:00/ CYE (REPETITION) 16:00/ SPECIAL SESSION - ESMO EMERGING COUNTRIES AND 09:00 Is hormone therapy really harmless in elderly people? 17:30 PUBLIC POLICY COMMITTEES Speaker: Matti Aapro, Genolier, Switzerland Availability of anti-neoplastic medicines in Europe Details to be announced 10:45/ ESMO Clinical Practice Guidelines 1 12:45 Chair: Enriqueta Felip, Barcelona, Spain 16:00/ JOINT SYMPOSIUM: ESMO - EONS Co-Chair: Nicholas Pavlidis, Ioannina, Greece 17:30 Oral tumour therapy: Collaboration and coordination of healthcare professional activities to enhance patient Introduction to the ESMO CP Guidelines adherence Enriqueta Felip, Barcelona, Spain Co-Chairs: Andrés Cervantes, Valencia, Spain and Questionnaire Anita Margulies, Zurich, Switzerland Nicholas Pavlidis, Ioannina, Greece Issues and challenges in oral tumour therapy adherence Advanced NSCLC case presentation Anita Margulies, Zurich, Switzerland Speaker: Stefan Zimmermann, Fribourg, Switzerland Clinical issues in patients receiving oral tumour therapy: How Discussant: Solange Peters, Lausanne, Switzerland can we improve adherence? Questions and answers Alfredo Carrato, Madrid, Spain Gastric marginal zone lymphoma or MALT type case presentation Nurse led clinics: Involvement in patient management and follow up Speaker: To be announced To be announced Discussant: Emanuele Zucca, Bellinzona, Switzerland Oral tumour therapy in Emerging Countries: Special problems Questions and answers encountered High-grade glioma case presentation Alexandru Eniu, Cluj Napoca, Romania Speaker: Katharina Seystahl, Zurich, Switzerland Options and strategies: Project in action: Oral tumour therapy- Discussant: Roger Stupp, Zurich, Switzerland adherence and safety Questions and answers Anita Margulies, Zurich, Switzerland Head & neck cancer: HPV case presentation Conclusions Speaker: To be announced Andrés Cervantes, Valencia, Spain Discussant: Lisa Licitra, Milan, Italy Questions and answers 13:45/ ESMO Clinical Practice Guidelines 2 15:45 Chair: Andrés Cervantes, Valencia, Spain Co-Chair: George Pentheroudakis, Ioannina, Greece Introduction to the ESMO CP Guidelines Andrés Cervantes, Valencia, Spain Questionnaire George Pentheroudakis, Ioannina, Greece Advanced melanoma case presentation Speaker: Simone Goldinger, Zurich, Switzerland Discussant: Reinhard Dummer, Zurich, Switzerland Questions and answers Gestational trophoblastic disease case presentation Speaker: Fieke Froeling, London, UK Discussant: Michael Seckl, London, UK Questions and answers Waldenström’s macroglobulinaemia case presentation Speaker: To be announced Discussant: Christian Buske, Ulm, Germany Questions and answers Cervical cancer case presentation Speaker: To be announced Discussant: Cristiana Sessa, Bellinzona, Switzerland Questions and answers

32 Session timings may be subject to change within the same day Monday, 29 September 2014 08:00/ CHALLENGE YOUR EXPERT (CYE) 14:15/ JOINT SYMPOSIUM: ESMO - SEOM 09:00 Current diagnosis and treatment of CUP 15:45 Investigation driven precision oncology Speaker: George Pentheroudakis, Ioannina, Greece Co-Chairs: Rolf A. Stahel, Zurich, Switzerland and Pilar Garrido, Madrid, Spain 09:15/ SPECIAL SESSION Introduction 10:45 Precision medicine: Panacea or false dawn? Pilar Garrido, Madrid, Spain Chair: Johann S. de Bono, Sutton, UK Translating breast cancer genomics into clinic Co-Chair: José Baselga, New York, NY, US Miguel Martin, Madrid, Spain Introduction Johann S. de Bono, Sutton, UK Can we do better with our current therapies for NSCLC? The Spanish Lung Cancer Group approach Visualising the true spectrum of cancer: Will we get convergence Rafael Rosell, Badalona, Spain from divergence? Peter Campbell, Cambridge, UK TTD contribution to precision oncology Enrique Aranda, Cordoba, Spain Drug registration strategies: How will these change with precision medicine? The European perspective of academic research: The way to José Baselga, New York, NY, US move forwards To be announced Intrapatient heterogeneity and clonal evolution: What precision medicine? Conclusions Charles Swanton, London, UK to be announced Precision medicine: Panacea or false dawn? 16:00/ EDUCATIONAL SESSION Andrew Hughes, Macclesfield, UK 17:30 Cancer in young adults (18-35) Conclusions Chair: Sophie Fosså, Oslo, Norway Johann S. de Bono, Sutton, UK Co-Chair: George Pentheroudakis, Ioannina, Greece Epidemiology, risk factors, genetics and molecular biology 11:00/ JOINT SYMPOSIUM: ESMO - ASCO Sophie Fosså, Oslo, Norway 12:30 The evolution of the clinical trials landscape Managing the most common tumours affecting young adults: Co-Chairs: Rolf A. Stahel, Zurich, Switzerland and Peculiarities, controversies and clinical research Peter Yu, Sunnyvale, CA, US Valerie Laurence, Paris, France Introduction Peter Yu, Sunnyvale, CA, US Follow up and long term toxicity of young adult cancer survivors Daniel Stark, Leeds, UK Novel molecular studies to inform the conduct of oncology clinical trials: from battle to master protocols 16:00/ SPECIAL SESSION - RARE CANCERS EUROPE Roy Herbst, New Haven, CT, US 17:30 How clinical trials could have been done, and were not, Adapting organisation and research infrastructures at Gustave in rare cancers Roussy for todays clinical research programmes Details to be announced Alexander M.M. Eggermont, Villejuif, France Can Collaborative Molecular Screening Platforms (CMSPs) Tuesday, 30 September 2014 support new forms of cancer clinical research? The example of the EORTC SPECTA programme 08.00/ CYE (REPETITION) Denis Lacombe, Brussels, Belgium 09:00 Current diagnosis and treatment of CUP The evolution of clinical trials: Randomised controlled trials to Speaker: George Pentheroudakis, Ioannina, Greece real world studies Gary Lyman, Seattle, WA, US 09:00/ CONGRESS HIGHLIGHTS 13:00 The best of the ESMO 2014 Congress Conclusions Rolf A. Stahel, Zurich, Switzerland

Controversy sessions will be included in the programme and details will be made available at the same time as the abstract-related sessions

Session timings may be subject to change within the same day 33 YOUNG ONCOLOGISTS (YO)

Friday, 26 September 2014 Monday, 29 September 2014 14:00/ YO MASTERCLASS 08:00/ YO BREAKFAST 17:00 ESMO YOs meet the EACR: Integrating basic science 08:45 Risks and boundaries: The doctor / cancer patient into clinical research relationship Chair: Raffaele Califano, Manchester, UK Session Coordinators: Mila Petrova, Sofia, Bulgaria and Co-Chair: Leticia De Mattos-Arruda, Barcelona, Spain Valentina Guarneri, Padua, Italy Functional characterisation of tumours using patient-derived Speaker: Lesley Fallowfield, Brighton, UK models - therapeutic implications Speaker: Joan Seoane, Barcelona, Spain 09:00/ YO FORUM Session Shooter: Matthias Preusser, Vienna, Austria 10:30 Tips and tricks for cancer researchers in training Chair: Valentina Guarneri, Padua, Italy Inter and intra-tumour genetic heterogeneity: Challenges for Co-Chair: targeted therapy Karin Jordan, Halle, Germany Speaker: Carlos Caldas, Cambridge, UK The ideal mentor and the impact on your career Session Shooter: Erika Martinelli, Naples, Italy Speaker: Peter Schmid, London, UK Circulating biomarkers: What does this mean today? Session Shooter: Mila Petrova, Sofia, Bulgaria Speaker: Klaus Pantel, Hamburg, Germany Practical advice on how to write a clinical trial protocol Session Shooter: Sophie Postel-Vinay, London, UK Speaker: To be announced Next generation of clinical trial design Session Shooter: Nikita Volkov, St. Petersburg, Russian Federation Speaker: Timothy Yap, Sutton, UK The importance of a well written grant application Session Shooter: Jesus Corral, Seville, Spain Speaker: Fatima Cardoso, Lisbon, Portugal 17:15/ VESALIUS TALK Session Shooter: Sophie Postel-Vinay, London, UK 17:45 Paving your own path to success Research project completed - now write your paper! Mentors: Christoph Zielinski, Vienna, Austria; Speaker: Kari Skinningsrud, Lillestrøm, Norway Angelo Di Leo, Prato, Italy and Nicholas Pavlidis, Ioannina, Greece Session Shooter: Camilla Qvortrup, Odense, Denmark 11:00/ YO SPECIAL SESSION Saturday, 27 September 2014 12:30 Fellowships in Europe: Educational opportunities for young oncologists 08:00/ YO BREAKFAST Chair: Giampaolo Tortora, Verona, Italy 08:45 How to address the media: Practical advice for young Co-Chair: Raffaele Califano, Manchester, UK oncologists Introduction Session Coordinators: Margaret Hutka, London, UK and Giampaolo Tortora, Verona, Italy Matthias Preusser, Vienna, Austria The ESMO Fellowship Programme Speaker: Jilly Carter, Wallingford, UK Susana Banerjee, London, UK Practical tips from a former fellow Sunday, 28 September 2014 Leticia De Mattos-Arruda, Barcelona, Spain Best fellowship project 1 08:00/ YO BREAKFAST Floriana Morgillo, Naples, Italy 08:45 How to find the right work-life balance: Time Best fellowship project 2 management for young oncologists Hatem A. Azim, Brussels, Belgium Session Coordinators: Giannis Mountzios, Athens, Greece and Susana Banerjee, London, UK Conclusions Raffaele Califano, Manchester, UK and Speaker: Pia Osterlund, Helsinki, Finland Giampaolo Tortora, Verona, Italy Awards: Presentation of the ESMO 2014 fellows and the 2013 best exam

YOUNG ONCOLOGISTS COMMITTEE Raffaele Califano, Manchester, UK, Chair Susana Banerjee, London, UK Erika Martinelli, Naples, Italy Jesus Corral, Seville, Spain Giannis Mountzios, Athens, Greece Evandro De Azambuja, Brussels, Belgium Mila Petrova, Sofia, Bulgaria Leticia De Mattos-Arruda, Barcelona, Spain Sophie Postel-Vinay, London, UK Valentina Guarneri, Padova, Italy Matthias Preusser, Vienna, Austria Margaret Hutka, London, UK Camilla Qvortrup, Odense, Denmark Karin Jordan, Halle, Germany Nikita Volkov, St. Petersburg, Russian Federation

34 Session timings may be subject to change within the same day STOP SEARCHING START FINDING

FIND WHAT YOU’RE LOOKING FOR ON ONCOLOGYPRO

THE ONLINE ACCESS TO ESMO’S SCIENTIFIC AND EDUCATIONAL CONTENT. Your one-stop shop for exclusive medical oncology content, from news and conference presentations to guidelines, handbooks and treatment factsheets. All available at your desk, or on the go. MEDICAL ONCOLOGY IS A FAST-EVOLVING FIELD, ONCOLOGYPRO WILL HELP YOU KEEP UP-TO-DATE.

oncologypro.esmo.org

Major sponsors

Main sponsors

ESM_OncoPRO2014_Ad_AdvProgramme_210x297mm.indd 1 07/03/14 13:28 PATIENT ADVOCACY TRACK

Saturday, 27 September 2014 Sunday, 28 September 2014 10:00/ Cancer research 10:00/ Capacity building 13:00 13:00 Clinical trials: Making statistics a little bit easier to understand! The ESMO “Patient Advocacy Best Practice Award” 2014 Clinical trials – Endpoints Why strategic planning is important and valuable for patient groups? Patient involvement in cancer clinical research 14:00/ Patient advocacy (Part 1) Introduction: Generating patient data, tissue and experiences… 15:30 14:00/ Treatment & living (part 1) An interesting journey through European healthcare politics 15:30 RARE CANCERS in EUROPE: More common than you think! ESMO Patient Cancer Guides 16:00/ Patient advocacy (Part 2) Cancer & nutrition 17:30 16:00/ Treatment & living (part 2) European cross border healthcare directive 17:45 17:30 End of the 2nd day – Farewell Patient interaction with multidisciplinary teams (MDTs) Highlighting some social challenges

17:45 End of the 1st day – Get together / Networking

ESMO PATIENT ADVOCACY TRACK TASK FORCE Lorenz Jost, Kantonsspital and Chair of the ESMO CPWG Switzerland Raphael Catane Anita Margulies Sheba Medical Centre, Israel European Oncology Nursing Society, Switzerland Philip Davies Kathy Oilver European Cervical Cancer Association, UK International Brain Tumours Alliance, UK Francesco De Lorenzo Zorana Stokic European Cancer Patient Coalition, Italy Europacolon, Serbia Louis Denis Wendy Tse Yared Europa Uomo, Belgium Association of European Cancer Leagues, Belgium Jan Geissler Stefania Vallone CML Advocates Network, Germany Global Lung Cancer Coalition, Italy Gabriela Kornek Anita Waldmann Medical University of Vienna, Austria Myeloma Euronet, Germany Stella Kyriakides Markus Wartenberg Europa Donna Cyprus, Cyprus Sarcoma Patients EuroNet, IKCC, Germany

Final details of the programme will be published online at esmocongress.org

36 Session timings may be subject to change within the same day esmocongress.org